◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

Name: GlaxoSmithKline Pharmaceuticals Limited（GLAXO）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Healthcare · ウォール街（米国） · 最終更新: 2026-09-20

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide.

主要指標

時価総額: ₹481 billion
売上高（2026-03-31 期末の会計年度）: ₹38.1B
当期純利益: ₹10.4B
売上総利益率: 62.7%
純利益率: 27.2%

インタラクティブチャートと全財務諸表を見る →

年次損益計算書

損益計算書	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
売上高合計	₹38.1B	₹37.3B	₹34.4B	₹32.3B	—
売上総利益	₹23.9B	₹22.5B	₹20.2B	₹18.7B	—
営業利益（EBIT）	₹12.5B	₹11.1B	₹8.4B	₹7.5B	—
当期純利益	₹10.4B	₹9.3B	₹5.9B	₹6.1B	—

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は GLAXO のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/GLAXO

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.